Bader D, Blondheim O, Jonas R, Admoni O, Abend-Winger M, Reich D, Lanir A, Tamir A, Eldar I, Attias D
Department of Neonatology, Bnai-Zion Medical Centre, Technion, Israel Institute of Technology, Haifa, Israel.
Acta Paediatr. 1996 Apr;85(4):496-501. doi: 10.1111/j.1651-2227.1996.tb14070.x.
Erythropoietin (rHuEPO) therapy has been shown to be beneficial in preventing and treating anaemia of prematurity and to decrease the need for blood transfusions. There is, however, only scanty data on the effect of rHuEPO therapy on iron metabolism. We studied 29 preterm infants (age 34 +/- 14 days) who were randomly assigned to receive either rHuEPO 900 U kg-1 week-1 with 6 mg kg-1 day-1 of iron for 4 weeks (n = 15) or no therapy. The following parameters were evaluated and compared between and within groups at the beginning, during and at the end of the study: Haematocrit (SI), reticulocytes (10(9) micrograms l-1), serum ferritin (microgram 1-1) and iron (mumol l-1). The results were as follows. At the baseline, erythropoietin levels were similar in both groups: 7.2 +/- 5.6 versus 6.2 +/- 3.2 mU ml-1 (NS). In the treated infants the haematocrit remained stable during the study and was significantly higher than in the control group by the end of the study: 0.34 +/- 0.03 versus 0.28 +/- 0.05 (p = 0.001). rHuEPO therapy increased the reticulocyte count from 130 +/- 70 to 430 +/- 200 (p = 0.0002). However, rHuEPO therapy depleted both serum ferritin and iron levels from 321 +/- 191 to 76 +/- 58 micrograms l-1 (p = 0.04) and from 18 +/- 5 to 13 +/- 4 mumol l-1 (p = 0.03), respectively. We conclude that rHuEPO therapy prevented anaemia and its sequelae; however, serum ferritin and iron levels were depleted. We suggest that the effect of rHuEPO may be further increased by higher iron supplementation.
促红细胞生成素（rHuEPO）治疗已被证明对预防和治疗早产儿贫血有益，并可减少输血需求。然而，关于rHuEPO治疗对铁代谢影响的数据却很少。我们研究了29名早产儿（年龄34±14天），他们被随机分为两组，一组接受每周每千克体重900单位的rHuEPO和每天每千克体重6毫克的铁，共治疗4周（n = 15），另一组不接受治疗。在研究开始、期间和结束时，对两组之间以及组内的以下参数进行了评估和比较：血细胞比容（SI）、网织红细胞（10⁹/微升）、血清铁蛋白（微克/升）和铁（微摩尔/升）。结果如下。在基线时，两组的促红细胞生成素水平相似：7.2±5.6对6.2±3.2毫国际单位/毫升（无显著性差异）。在接受治疗的婴儿中，血细胞比容在研究期间保持稳定，到研究结束时显著高于对照组：0.34±0.03对0.28±0.05（p = 0.001）。rHuEPO治疗使网织红细胞计数从130±70增加到430±200（p = 0.0002）。然而，rHuEPO治疗使血清铁蛋白和铁水平分别从321±191微克/升降至76±58微克/升（p = 0.04）和从18±5微摩尔/升降至13±4微摩尔/升（p = 0.03）。我们得出结论，rHuEPO治疗可预防贫血及其后遗症；然而，血清铁蛋白和铁水平会降低。我们建议，通过增加铁补充量可能会进一步提高rHuEPO的疗效。
